Alkem Laboratories

Motilal Oswal

FINANCIAL SERVICES

Estimate change	1
TP change	1
Rating change	

Bloomberg	ALKEM IN
Equity Shares (m)	120
M.Cap.(INRb)/(USDb)	637 / 7.7
52-Week Range (INR)	5420 / 2835
1, 6, 12 Rel. Per (%)	2/15/43
12M Avg Val (INR M)	846

Financials & Valuations (INR b)

Y/E MARCH	FY24E	FY25E	FY26E
Sales	128.7	144.8	161.2
EBITDA	23.7	27.1	30.6
Adj. PAT	19.6	21.6	23.4
EBIT Margin (%)	16.2	16.5	16.9
Cons. Adj. EPS (INR)	164.0	180.9	196.0
EPS Gr. (%)	54.6	10.3	8.4
BV/Sh. (INR)	877.1	1,017.3	1,169.2
Ratios			
Net D:E	-0.2	-0.2	-0.3
RoE (%)	20.1	19.1	17.9
RoCE (%)	18.6	17.9	16.9
Payout (%)	22.5	22.5	22.5
Valuations			
P/E (x)	32.6	29.5	27.2
EV/EBITDA (x)	26.1	22.5	19.6
Div. Yield (%)	0.6	0.6	0.7
FCF Yield (%)	1.7	2.0	1.7
EV/Sales (x)	4.8	4.2	3.7

Shareholding pattern (%)

As On	Dec-23	Sep-23	Dec-22
Promoter	56.7	56.7	57.2
DII	15.9	17.6	16.4
FII	8.5	6.0	4.4
Others	18.9	20.9	22.0

FII Includes depository receipts

CMP: INR5,328 TP: INR5,160 (-3%) Neutral India, international (ex-US) businesses outperforms

Steps up investments in biosimilar segment

- Alkem Lab (ALKEM) delivered better-than-expected 3QFY24 earnings. While sales were largely in line with estimates, margin came in above our estimate owing to controlled cost base. ALKEM continued to exhibit strong growth momentum in the international (Ex-US) business.
- We raise our earnings estimates by 10%/5%/6% for FY24/FY25/FY26 to factor in reduced operating costs/better productivity, a robust show in international business, and an improved outlook for the biosimilar segment.
 We value ALKEM at 25x 12M forward earnings to arrive at a TP of INR5,160.
 We expect 12%/14%/9% YoY growth in revenue/EBITDA/PAT over FY24-26, driven by a 13%/21%/7% sales CAGR in domestic formulation (DF), international (ex-US), and the US segments. We also expect a 60bp margin improvement. While growth prospects remain better in key segments, we maintain our Neutral rating on the stock as the current valuation adequately factors in the upside in earnings.

Lower RM costs and stable opex drive margin on YoY/QoQ basis

- 3QFY24 revenue grew 9% YoY to INR33b (in line). Domestic business grew 12% YoY to INR22b (69% of sales). International business grew 3% YoY to INR10.2b. Within international business, Other International sales grew 47% YoY to INR3.4b (10% of sales). US sales declined 10% YoY to INR6.8b (21% of sales).
- Gross margin expanded by 180bp YoY to 60.8% due to low raw material prices.
- EBITDA margin expanded by 160bp YoY to 21.3% (our est: 18.2%) due to higher GM and lower R&D/employee costs (-90bp/-10bp YoY as % of sales), offset by higher other expenses (+120bp YoY as % of sales).
- Accordingly, EBITDA increased by 18% YoY to INR7.1b (vs. est. of INR5.9b).
- Adj. PAT grew 41% YoY to INR6.4b (our est: INR4.5b) due to higher other income (>2x YoY) and a lower tax rate of 7.7% (vs. 14.6% in 3QFY23).
- For 9MFY24, revenue/EBITDA/PAT grew 12%/39%/65% YoY to INR97b/ INR18b/INR16b.

Highlights from the management commentary

- ALKEM expects 17% EBITDA margin in FY24 and is making efforts to improve margins from these levels going forward.
- Other expenses fell QoQ due to lower distribution expenses related to freight.
- The company plans to invest INR2.5b to build a manufacturing facility in the US for the biosimilar segment.
- With improved traction in biosimilar products (7 launched in India), the company would introduce these products in other geographies as well.
- ALKEM expects Pen-G prices to remain high.

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Research Analyst: Sumit Gupta (Sumit.G@MotilalOswal.com) | Akash Manish Dobhada (Akash.Dobhada@MotilalOswal.com

Investors are advised to refer through important disclosures made at the last page of the Research Report. Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Ouarterly Perf. (Consolidated)

Y/E March		FY23	}			FY24	E		FY23E	FY24E		Var
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3QE	%
Net Revenues	25.8	30.8	30.4	29.0	29.7	34.4	33.2	31.4	116.0	128.7	32.4	2.5
YoY Change (%)	-5.7	10.0	16.1	16.9	15.2	11.7	9.3	8.1	9.1	10.9	6.6	
Total Expenditure	23.0	26.3	24.4	25.5	25.8	26.9	26.2	26.1	64.4	65.7	26.2	
EBITDA	2.7	4.5	6.0	3.5	3.9	7.5	7.1	5.2	16.8	23.7	5.9	19.9
YoY Change (%)	-53.9	-27.3	20.2	4.8	42.4	64.5	18.1	48.4	-18.2	41.0	(1.5)	
Margins (%)	10.6	14.7	19.7	12.2	13.1	21.7	21.3	16.7	14.5	18.4	18.2	
Depreciation	0.8	0.8	0.8	0.8	0.7	0.7	0.7	0.7	3.1	2.9	0.7	
EBIT	2.0	3.8	5.2	2.7	3.2	6.7	6.4	4.5	13.7	20.8	5.2	
YoY Change (%)	-62.3	-31.7	23.7	8.2	60.8	78.7	22.6	64.5	-21.0	18.9	(0.9)	
Margins (%)	7.6	12.2	17.1	9.5	10.7	19.6	19.2	14.4	11.8	16.2	15.9	
Interest	0.3	0.2	0.3	0.3	0.3	0.3	0.3	0.2	1.1	1.1	0.3	
Other Income	0.5	0.5	0.5	0.7	0.7	0.6	0.9	0.6	2.2	2.8	0.7	
PBT before EO Exp	2.2	4.0	5.4	3.1	3.5	7.1	7.1	4.9	14.8	22.5	5.5	27.8
EO Exp/(Inc)	0.7	0.0	0.0	1.0	0.0	0.6	0.5	0.0	1.7	1.1	-	
PBT after EO Exp	1.5	4.0	5.4	2.1	3.5	6.5	6.5	4.9	13.0	21.4	5.5	
Тах	0.2	0.5	0.8	1.4	0.7	0.3	0.5	1.1	3.0	2.6	0.9	
Rate (%)	13.5	13.6	14.6	68.0	18.4	5.1	7.7	22.3	20.2	11.4	16.0	
PAT (pre Minority Interest)	1.3	3.5	4.6	0.7	2.9	6.1	6.0	3.8	10.1	18.9	4.6	
Minority Interest	0.0	0.2	0.1	0.0	0.0	-0.1	0.1	0.2	0.2	0.3	0.1	
Reported PAT	1.3	3.3	4.5	0.7	2.9	6.2	5.9	3.6	9.8	18.6	4.5	31.6
Adj Net Profit	1.9	3.3	4.5	2.9	2.9	6.8	6.4	3.6	12.7	19.6	4.5	42.0
YoY Change (%)	-59.8	-39.7	12.2	28.2	52.3	104.1	41.3	21.6	-23.2	54.6	-0.6	

Key performance Indicators (Consolidated)

Y/E March		FY2	3			FY24	ŀΕ		FY23E	FY24E
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE		
India formulations	17.8	22.2	19.9	20.1	19.0	23.3	22.3	22.2	80.0	86.8
YoY Change (%)	(6.7)	13.0	9.7	17.0	6.7	5.0	12.1	10.4	8.1	8.5
US generics	5.6	6.0	7.6	5.9	7.0	7.7	6.8	6.8	25.1	28.2
YoY Change (%)	(7.9)	(0.9)	32.8	9.2	25.0	27.1	(10.2)	14.5	7.9	12.4
International (Ex-US)	2.0	2.3	2.3	2.7	3.2	2.9	3.4	3.2	9.3	12.7
YoY Change (%)	9.6	15.2	17.1	33.3	56.5	27.3	46.9	21.5	18.9	37.0
Cost Break-up										
RM Cost (% of Sales)	42.5	42.4	41.1	43.3	40.4	38.6	39.2	39.9	42.3	39.5
Staff Cost (% of Sales)	20.7	18.5	17.3	17.3	19.1	16.1	17.2	18.6	18.4	17.7
R&D Expenses(% of Sales)	5.1	4.2	4.3	5.1	4.1	3.4	3.3	4.0	4.7	3.6
Other Cost (% of Sales)	21.1	20.0	17.7	22.2	23.3	20.2	18.9	22.8	20.2	20.8
Gross Margins(%)	57.5	57.6	58.9	56.7	59.6	61.4	60.8	60.1	57.7	60.5
EBITDA Margins(%)	10.6	14.7	19.7	12.2	13.1	21.7	21.3	16.7	14.5	18.4
EBIT Margins(%)	7.6	12.2	17.1	9.5	10.7	19.6	19.2	14.4	11.8	16.2



Management call highlights

- ALKEM witnessed low single-digit price erosion in US generics base business.
- The company outperformed the industry in GI as well as anti-diabetic segment in the DF segment.
- It has no plans to add MRs over the medium term in the DF segment.
- Chronic therapies formed 17% of DF segment for the quarter.
- NLEM portfolio is about 32% of DF segment.

Key exhibits





Source: MOFSL, Company




Exhibit 2: US sales increased 10% YoY in 3QFY24

Source: MOFSL, Company






Exhibit 4: Robust ANDA pip	peline
----------------------------	--------

US Filings	# Nos.
Total ANDAs filed	173
ANDAs filed in 3QFY24	0
NDAs	0
	Source: MOFSL, Company

Building growth levers in addition to DF/exports

DF: Robust performance in chronic therapies; maintain leading position in anti-infective segment

- In 9MFY24, ALKEM's DF business grew 8% YoY to INR65b due to strong growth across chronic therapies.
- During 9MFY24, the chronic portfolio outperformed IPM. However, on an overall basis, ALKEM has underperformed IPM growth due to muted performance in acute therapy because of the delayed monsoon.
- In 9MFY24, ALKEM delivered strong growth in the chronic segment, with antidiabetic/GI/Derma segments growing 22.9%/11.2%/9.4% YoY vs. 5.6%/7.7%/5.7% YoY for IPM. The neuro segment grew in line with IPM in 9MFY24.
- Accordingly, we expect ALKEM to register a 12.5% sales CAGR in DF to INR110b over FY24-26.

US: focus on niche products/market share gain to fuel growth

In 9MY24, US sales grew 12% YoY to INR21b (up 6% at USD260m in cc terms) due to market share gains in the existing products and reduced intensity of price erosion.

Source: MOFSL, Company

MOTILAL OSWAL


- In 9MFY24, the company filed four ANDAs and received 17 final approvals. It has 173 ANDAs filed and has 146 final approvals to date.
- Overall, we expect ALKEM to deliver a 6.3% sales CAGR in the US to reach ~USD394m over FY24-26.

Building blocks in biosimilar segment

- ALKEM has not only developed products in the biosimilar segment, but also commercialized a few products in India.
- Further, it plans to invest INR2.5b in building the manufacturing facility in the US for commercial production of biosimilar products.
- Overall, ALKEM is expected to achieve break-even in FY24 and expects profitability-led growth in this segment in coming years.

Maintain Neutral


- We raise our earnings estimates by 10%/5%/6% for FY24/FY25/FY26, factoring in lower operating costs/better productivity, a robust show in international business, and an improved outlook for its biosimilar segment. We value ALKEM at 25x 12M forward earnings to arrive at a TP of INR5,160.
- We expect 12%/14%/9% YoY growth in revenue/EBITDA/PAT over FY24-26, driven by a 13%/21%/7% sales CAGR in DF/International (Ex-US)/US. We also expect a 60bp margin improvement. While prospects remain better in key segments, we maintain our Neutral stance on the stock as the current valuation adequately factors in the upside in earnings.



Source: MOFSL, Company, Bloomberg


Source: MOFSL, Company, Bloomberg

Story in charts




Source: Company, MOFSL

Exhibit 9: EBITDA margin expanded 160bp YoY




Source: Company, MOFSL

Exhibit 8: Gross margin expanded 180bp YoY in 3QFY24




Source: Company, MOFSL

Exhibit 10: EPS increased 41% YoY to ~INR54 in 3QFY24



Source: Company, MOFSL

Story in charts



10 February 2024

FY18 FY19 FY20 FY21 FY22 FY23 FY24E FY25E FY26E

Source: Company, MOFSL

Source: Company, MOFSL

FY18 FY19 FY20 FY21 FY22 FY23 FY24E FY25E FY26E

Financials and Valuations

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E
Total Income from Operations	73,572	83,444	88,505	106,342	115,993	128,690	144,800	161,227
Change (%)	14.4	13.4	6.1	20.2	9.1	10.9	12.5	11.3
Total Expenditure	62,401	68,484	68,426	85,813	99,198	105,011	117,723	130,594
% of Sales	84.8	82.1	77.3	80.7	85.5	81.6	81.3	81.0
EBITDA	11,171	14,960	20,079	20,529	16,795	23,679	27,078	30,633
Margin (%)	15.2	17.9	22.7	19.3	14.5	18.4	18.7	19.0
Depreciation	1,932	2,348	2,746	3,040	3,104	2,881	3,169	3,433
EBIT	9,239	12,612	17,333	17,490	13,690	20,798	23,909	27,201
Int. and Finance Charges	546	651	589	524	1,074	1,102	964	895
Other Income	877	1,042	1,867	1,627	2,161	2,816	3,143	3,400
PBT bef. EO Exp.	9,570	13,004	18,611	18,592	14,778	22,513	26,087	29,705
EO Items	-23	-406	-190	-150	-1,730	-1,090	0	0
PBT after EO Exp.	9,547	12,598	18,421	18,443	13,048	21,423	26,087	29,705
Current Tax	1,810	1,105	2,243	1,640	2,980	2,571	4,174	5,941
Deferred Tax	0	0	0	0	0	0	0	0
Tax Rate (%)	19.0	8.8	12.2	8.9	22.8	12.0	16.0	20.0
Less: Minority Interest	131	222	328	300	226	256	289	327
Reported PAT	7,606	11,271	15,850	16,503	9,842	18,596	21,624	23,438
Adjusted PAT	7,629	11,407	16,100	16,516	12,678	19,600	21,624	23,438
Change (%)	8.4	49.5	41.1	2.6	-23.2	54.6	10.3	8.4
Margin (%)	10.4	13.7	18.2	15.5	10.9	15.2	14.9	14.5

Consolidated - Balance Sheet								INRm
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E
Equity Share Capital	239	239	239	239	239	239	239	239
Total Reserves	54,154	61,368	73,528	86,140	90,214	104,623	121,379	139,539
Net Worth	54,393	61,607	73,767	86,379	90,453	104,862	121,618	139,779
Minority Interest	1,326	1,483	1,813	2,094	3,897	3,897	3,897	3,897
Deferred Tax Liabilities	3	0	0	0	0	0	0	0
Total Loans	9,026	16,628	17,336	26,466	13,775	13,775	13,775	13,775
Capital Employed	64,748	79,717	92,916	114,939	108,125	122,534	139,290	157,450
Gross Block	26,000	30,354	32,376	35,948	36,835	41,017	44,624	48,147
Less: Accum. Deprn.	4,944	7,291	10,037	13,077	16,181	19,061	22,230	25,662
Net Fixed Assets	21,056	23,063	22,339	22,871	20,654	21,956	22,394	22,485
Goodwill on Consolidation	4,248	6,017	5,591	6,146	4,796	4,796	4,796	4,796
Capital WIP	4,930	3,630	3 <i>,</i> 933	3,395	3,103	2,321	2,215	2,194
Total Investments	3,236	2,614	3,328	3,710	6,218	6,218	6,218	6,218
Curr. Assets, Loans&Adv.	41,535	54,784	68,923	91,477	89,770	105,574	126,277	148,159
Inventory	14,999	18,188	23,124	30,055	26,075	28,770	33,220	36,852
Account Receivables	12,484	16,494	16,072	18,846	21,322	24,328	28,563	36,663
Cash and Bank Balance	6,616	10,922	19,905	25,786	25,786	34,073	43,786	51,588
Loans and Advances	7,437	9,180	9,822	16,790	16,587	18,403	20,707	23,056
Curr. Liability & Prov.	17,334	19,716	22,277	25,753	29,442	31,355	35,635	39,426
Account Payables	9,623	9,541	10,694	11,734	11,650	13,234	15,159	16,816
Other Current Liabilities	4,436	6,108	6,709	7,955	10,370	11,506	12,946	14,414
Provisions	3,275	4,067	4,874	6,064	7,421	6,616	7,531	8,196
Net Current Assets	24,202	35,068	46,647	65,725	60,329	74,219	90,641	108,732
Deferred Tax assets	7,076	9,326	11,079	13,093	13,025	13,025	13,025	13,025
Appl. of Funds	64,748	79,717	92,916	114,939	108,125	122,534	139,290	157,450

Financials and Valuations

Ratios								
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E
Basic (INR)								
EPS	63.8	95.4	134.7	138.1	106.0	164.0	180.9	196.0
Cash EPS	80.0	115.1	157.6	163.6	132.0	188.0	207.4	224.8
BV/Share	455	515	617	723	757	877	1,017	1,169
DPS	15.0	17.9	27.8	27.6	16.5	29.6	34.4	37.2
Payout (%)	28.5	22.5	24.9	23.7	23.7	22.5	22.5	22.5
Valuation (x)								
P/E	83.7	56.0	39.7	38.7	50.4	32.6	29.5	27.2
Cash P/E	66.8	46.4	33.9	32.7	40.5	28.4	25.8	23.8
P/BV	11.7	10.4	8.7	7.4	7.1	6.1	5.3	4.6
EV/Sales	8.7	7.7	7.2	6.0	5.4	4.8	4.2	3.7
EV/EBITDA	57.4	43.1	31.7	31.1	37.3	26.1	22.5	19.6
Dividend Yield (%)	0.3	0.3	0.5	0.5	0.3	0.6	0.6	0.7
FCF per share	21.1	19.9	90.4	65.5	152.5	92.1	106.2	91.2
Return Ratios (%)								
RoE	14.8	19.7	23.8	20.6	14.3	20.1	19.1	17.9
ROCE	13.6	17.6	19.9	17.1	11.3	18.6	17.9	16.9
RoIC	15.8	20.5	23.7	21.6	13.6	23.9	24.1	23.6
Working Capital Ratios								
Fixed Asset Turnover (x)	2.8	2.7	2.7	3.0	3.1	3.1	3.2	3.3
Asset Turnover (x)	1.1	1.0	1.0	0.9	1.1	1.1	1.0	1.0
Inventory (Days)	74	80	95	103	82	82	84	83
Debtor (Days)	62	72	66	65	67	69	72	83
Creditor (Days)	48	42	44	40	37	38	38	38
Working Cap. Turnover (Days)	87	106	110	137	109	114	118	129
Leverage Ratio (x)								
Current Ratio	2.4	2.8	3.1	3.6	3.0	3.4	3.5	3.8
Interest Cover Ratio	16.9	19.4	29.4	33.4	12.8	18.9	24.8	30.4
Debt/Equity	0.0	0.1	0.0	0.0	-0.1	-0.2	-0.2	-0.3
Consolidated - Cash Flow Statement								INRm
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E	FY26E
OP/(Loss) before Tax	9,547	12,598	18,421	18,443	14,778	22,513	26,087	29,705
Depreciation	1,932	2,528	2,746	3,040	3,104	2,881	3,169	3,433
Interest & Finance Charges	134	19	-312	-703	-1,087	-1,714	-2,178	-2,505
Direct Taxes Paid	-2,511	-2,834	-4,007	-3,969	-2,980	-2,571	-4,174	-5,941
(Inc)/Dec in WC	-1,403	-6,472	-3,412	-5,450	3,666	-6,693	-6,710	-10,289
CF from Operations	7,698	5,839	13,436	11,361	17,481	14,415	16,194	14,403
Others	98	12	-787	-250	0	0	0	0
CF from Operating incl EO	7,797	5,851	12,649	11,110	17,481	14,415	16,194	14,403
(Inc)/Dec in FA	-5,269	-3,477	-1,845	-3,280	755	-3,400	-3,502	-3,502
Free Cash Flow	2,527	2,374	10,805	7,830	18,237	11,015	12,692	10,901
(Pur)/Sale of Investments	1,235	458	3	-12,051	-2,508	0	0	0
Others	871	-4,395	-8,144	980	2,161	2,816	3,143	3,400
CF from Investments	-3,164	-7,414	-9,985	-14,351	408	-584	-359	-102
Inc/(Dec) in Debt	-1,057	6,031	1,397	8,628	-12,691	0	0	0
Interest Paid	-546	-651	-536	-401	-1,074	-1,102	-964	-895
Dividend Paid	-2,186	-4,396	-3,348	-4,219	-2,332	-4,187	-4,869	-5,277
CF from Fin. Activity	-3,789	791	-2,718	3,796	-16,324	-5,545	-6,122	-6,499
Inc/Dec of Cash	843	-771	-54	555	1,565	8,287	9,713	7,802
Opening Balance	1,667	2,490	1,759	1,705	2,297	3,862	12,149	21,862
Add/(less) Forex diff in Cash and Cash eq	-20	40	_,	37	_,,	-,002	,	,
Closing Cash and Cash Eq.	2,490	1,759	1,705	2,297	3,862	12,149	21,862	29,664
Pank Balancos	4 126	0 162	19 100	2,257	21 024	21 024	21,002	21,004

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

18,199

19,905

23,489

25,786

21,924

25,786

21,924

34,073

21,924

43,786

9,163

10,922

4,126

6,616

Bank Balances

Total Cash and Cash Eq.

21,924

51,588

Explanation of Investment Rating						
Investment Rating	Expected return (over 12-month)					
BUY	>=15%					
SELL	< - 10%					
NEUTRAL	< - 10 % to 15%					
UNDER REVIEW	Rating may undergo a change					
NOT RATED	ATED We have forward looking estimates for the stock but we refrain from assigning recommendation					

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even

though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

A graph of daily closing prices of securities is available at <u>www.nseindia.com</u>, <u>www.bseindia.com</u>. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views. **Regional Disclosures (outside India)**

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

Disclosures

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered brokerdealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act of Singapore .Accordingly, if a Singapore person is not, or ceases to be, such an investor, they must immediately discontinue any use of this Report and inform MOCMSPL .

Specific Disclosures

- MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- Research Analyst has not served as director/officer/employee in the subject company 5
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- MOFSL has not received compensation for investment banking/merchant banking/brokerage services from the subject company in the past 12 months MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company

- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085. Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.